DK3897738T5 - Saponin-konjugater - Google Patents
Saponin-konjugater Download PDFInfo
- Publication number
- DK3897738T5 DK3897738T5 DK19817673.7T DK19817673T DK3897738T5 DK 3897738 T5 DK3897738 T5 DK 3897738T5 DK 19817673 T DK19817673 T DK 19817673T DK 3897738 T5 DK3897738 T5 DK 3897738T5
- Authority
- DK
- Denmark
- Prior art keywords
- saponin conjugates
- saponin
- conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/595—Polyamides, e.g. nylon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
- A61K47/6885—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy the conjugate or the polymer being a starburst, a dendrimer, a cascade
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/256—Polyterpene radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2022283 | 2018-12-21 | ||
| NL2023468 | 2019-07-10 | ||
| NL2023568 | 2019-07-25 | ||
| PCT/EP2019/084190 WO2020126604A1 (en) | 2018-12-21 | 2019-12-09 | Saponin conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK3897738T3 DK3897738T3 (da) | 2024-02-19 |
| DK3897738T5 true DK3897738T5 (da) | 2024-08-05 |
Family
ID=71101079
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19817673.7T DK3897738T5 (da) | 2018-12-21 | 2019-12-09 | Saponin-konjugater |
| DK19817689.3T DK3897735T3 (da) | 2018-12-21 | 2019-12-09 | Biologisk aktiv klynge af molekyler |
| DK19835231.2T DK3773737T3 (da) | 2018-12-21 | 2019-12-09 | Saponin konjugeret til epitop-bindende proteiner |
| DK21212184.2T DK4015003T5 (da) | 2018-12-21 | 2019-12-09 | Forbedret antistof-oligonukleotid-konjugat |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19817689.3T DK3897735T3 (da) | 2018-12-21 | 2019-12-09 | Biologisk aktiv klynge af molekyler |
| DK19835231.2T DK3773737T3 (da) | 2018-12-21 | 2019-12-09 | Saponin konjugeret til epitop-bindende proteiner |
| DK21212184.2T DK4015003T5 (da) | 2018-12-21 | 2019-12-09 | Forbedret antistof-oligonukleotid-konjugat |
Country Status (15)
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015367378A1 (en) | 2014-12-17 | 2017-06-15 | Proqr Therapeutics Ii B.V. | Targeted RNA editing |
| EP3475424A1 (en) | 2016-06-22 | 2019-05-01 | ProQR Therapeutics II B.V. | Single-stranded rna-editing oligonucleotides |
| WO2018041973A1 (en) | 2016-09-01 | 2018-03-08 | Proqr Therapeutics Ii B.V. | Chemically modified single-stranded rna-editing oligonucleotides |
| JP7373998B2 (ja) | 2017-05-02 | 2023-11-06 | コーネル・ユニバーシティー | 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬 |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| US20220023433A1 (en) * | 2018-12-21 | 2022-01-27 | Sapreme Technologies B.V. | Saponin Conjugates |
| BR112022001389A8 (pt) * | 2019-07-25 | 2023-04-25 | Univ Berlin Charite | Derivados de saponina com janela terapêutica melhorada |
| EP3838910B1 (en) * | 2019-12-18 | 2022-09-28 | Freie Universität Berlin | Efficient gene delivery tool with a wide therapeutic margin |
| CN113527497B (zh) * | 2020-04-16 | 2022-06-10 | 上海洛启生物医药技术有限公司 | 抗Trop2纳米抗体及其应用 |
| EP4171645A2 (en) * | 2020-06-24 | 2023-05-03 | Sapreme Technologies B.V. | Hydrazone-based saponin derivatives |
| CA3183887A1 (en) * | 2020-06-24 | 2021-12-30 | Ruben POSTEL | Combination comprising an adc or an aoc comprising a vhh, and a saponin or a ligand-saponin conjugate |
| EP4117730A1 (en) * | 2020-06-24 | 2023-01-18 | Sapreme Technologies B.V. | Conjugate of saponin and single-domain antibody, pharmaceutical composition comprising said conjugate, therapeutic use thereof |
| JP7652807B2 (ja) * | 2020-06-24 | 2025-03-27 | サプリーム テクノロジーズ,ベー.フェー. | 単一ドメイン抗体、サポニン及びエフェクター分子のコンジュゲート、それを含む医薬組成物、前記医薬組成物の治療的使用 |
| EP4596052A3 (en) * | 2020-06-24 | 2025-11-05 | Sapreme Technologies B.V. | Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof |
| KR20230043113A (ko) * | 2020-06-24 | 2023-03-30 | 사프렘 테크놀로지스 비.브이. | 의약용 사포닌 유도체 |
| US20230263897A1 (en) * | 2020-06-24 | 2023-08-24 | Sapreme Technologies B.V. | Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate |
| CA3183881A1 (en) * | 2020-06-24 | 2021-12-30 | Sapreme Technologies B.V. | Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof |
| WO2021261995A1 (en) * | 2020-06-24 | 2021-12-30 | Sapreme Technologies B.V. | Combination of an antibody-drug conjugate and an antibody-saponin conjugate |
| US20240327829A1 (en) * | 2020-09-10 | 2024-10-03 | Sapreme Technologies B.V. | Conjugate of saponin, oligonucleotide and galnac |
| WO2022055352A1 (en) * | 2020-09-10 | 2022-03-17 | Sapreme Technologies B.V. | Semicarbazone-based saponin conjugate |
| EP4210761B8 (en) * | 2020-09-10 | 2025-09-24 | Sapreme Technologies B.V. | Semicarbazone-based saponin conjugate |
| WO2022055351A1 (en) * | 2020-09-10 | 2022-03-17 | Sapreme Technologies B.V. | Conjugate of saponin, oligonucleotide and galnac |
| WO2022072718A1 (en) | 2020-09-30 | 2022-04-07 | Nobell Foods, Inc. | Recombinant milk proteins and food compositions comprising the same |
| US10947552B1 (en) | 2020-09-30 | 2021-03-16 | Alpine Roads, Inc. | Recombinant fusion proteins for producing milk proteins in plants |
| US10894812B1 (en) | 2020-09-30 | 2021-01-19 | Alpine Roads, Inc. | Recombinant milk proteins |
| EP4251206A4 (en) * | 2020-11-24 | 2025-12-24 | Brickbio Inc | PROTEIN DERIVATIVES CONTAINING UNNATURAL AMINO ACIDS AND BRANCHED BINDERS |
| US20240115712A1 (en) | 2021-01-26 | 2024-04-11 | Sapreme Technologies B.V. | Semicarbazone-based saponin conjugate |
| WO2022178754A1 (en) * | 2021-02-25 | 2022-09-01 | Shanghai Allygen Biologics Co., Ltd. | Targeting conjugates with therapeutic agents and oligonucleotides and uses thereof |
| WO2022265493A1 (en) * | 2021-06-18 | 2022-12-22 | Sapreme Technologies B.V. | Conjugate of saponin, oligonucleotide and galnac |
| WO2023038517A1 (en) | 2021-09-09 | 2023-03-16 | Sapreme Technologies B.V. | Semicarbazone-based saponin conjugate |
| WO2023121447A1 (en) * | 2021-12-22 | 2023-06-29 | Sapreme Technologies B.V. | Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition |
| EP4452281A1 (en) | 2021-12-22 | 2024-10-30 | Sapreme Technologies B.V. | Compositions comprising therapeutic nucleic acid and saponin for the treatment of muscle-wasting disorders |
| CA3240612A1 (en) | 2021-12-22 | 2023-06-29 | Miriam Verena Bujny | Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders |
| US20250082759A1 (en) | 2021-12-22 | 2025-03-13 | Sapreme Technologies B.V. | Compositions comprising therapeutic nucleic acid and targeted saponin for the treatment of muscle-wasting disorders |
| WO2023249473A1 (ko) * | 2022-06-24 | 2023-12-28 | 주식회사 피노바이오 | 하나의 항체에 2종의 약물-링커 접합체가 연결된 항체-약물 접합체 |
| EP4555085A1 (en) | 2022-07-15 | 2025-05-21 | ProQR Therapeutics II B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| EP4555086A1 (en) | 2022-07-15 | 2025-05-21 | ProQR Therapeutics II B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
| WO2024046622A1 (en) * | 2022-09-01 | 2024-03-07 | Sapreme Technologies B.V. | Compositions of polyplexes and saponins |
| EP4331610A1 (en) * | 2022-09-01 | 2024-03-06 | Sapreme Technologies B.V. | Polyplex-saponin covalent conjugate |
| EP4331609A1 (en) * | 2022-09-01 | 2024-03-06 | Sapreme Technologies B.V. | Methods and compositions for enhanced polyplex delivery |
| CN116259371B (zh) * | 2022-09-09 | 2026-02-17 | 江苏理工学院 | 化合物激素受体活性预测方法和装置 |
| US20240280568A1 (en) * | 2023-02-13 | 2024-08-22 | Nautilus Subsidiary, Inc. | Affinity reagents having artificial polymer scaffolds |
| CN118852442A (zh) | 2023-04-26 | 2024-10-29 | 上海麦科思生物医药有限公司 | 抗ptk7抗体及其用途 |
| JP2026522541A (ja) * | 2023-05-18 | 2026-07-08 | ヴィセリックス・インコーポレーティッド | 生物製剤の時空間的に制御されたペイロード送達のための形質膜埋込み型システム |
| WO2024261042A1 (en) | 2023-06-21 | 2024-12-26 | Sapreme Technologies B.V. | Conjugates of saponin and antisense oligonucleotides for use in the treatment of neurodegenerative diseases |
| JP2026521777A (ja) | 2023-06-21 | 2026-07-01 | サプリーム テクノロジーズ,ベー.フェー. | 中枢神経系障害を処置するための医薬組成物 |
| WO2025222234A1 (en) * | 2024-04-24 | 2025-10-30 | Starpharma Pty Ltd | Targeted dendrimer conjugates |
| EP4684805A1 (en) * | 2024-07-24 | 2026-01-28 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Selective antibody-drug conjugates for targeted cancer therapy |
| WO2026087678A1 (en) | 2024-10-24 | 2026-04-30 | Sapreme Technologies B.V. | Treatment for renal disorders |
| WO2026087695A1 (en) | 2024-10-24 | 2026-04-30 | Sapreme Technologies B.V. | Treatment for metabolic disorder |
| WO2026087680A1 (en) | 2024-10-24 | 2026-04-30 | Sapreme Technologies B.V. | Treatment for cardiovascular disease |
| WO2026119464A1 (en) | 2024-12-03 | 2026-06-11 | Sapreme Technologies B.V. | Treatment for cns-related disease |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0058021A3 (en) | 1981-02-06 | 1982-10-27 | Beecham Group Plc | Pharmaceutical compositions |
| US5591829A (en) | 1987-05-29 | 1997-01-07 | Matsushita; Shuzo | Antibodies modified with toxic substance |
| US5583112A (en) * | 1987-05-29 | 1996-12-10 | Cambridge Biotech Corporation | Saponin-antigen conjugates and the use thereof |
| US5273965A (en) | 1992-07-02 | 1993-12-28 | Cambridge Biotech Corporation | Methods for enhancing drug delivery with modified saponins |
| US5856571A (en) | 1995-06-07 | 1999-01-05 | Cellpro, Incorporated | Semicarbazide-containing linker compounds for formation of stably-linked conjugates and methods related thereto |
| NZ500779A (en) * | 1997-05-20 | 2001-06-29 | Galenica Pharmaceuticals Inc | Triterpene saponin analogs having adjuvant and immunostimulatory activity |
| US6262029B1 (en) * | 1998-08-14 | 2001-07-17 | Galenica Pharmaceuticals, Inc. | Chemically modified saponins and the use thereof as adjuvants |
| US7256257B2 (en) * | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| WO2003069997A1 (en) * | 2002-02-04 | 2003-08-28 | Corixa Corporation | Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins |
| US7112573B2 (en) * | 2002-04-19 | 2006-09-26 | Iowa Research, The University Foundation | Isoflavone and triterpene glycosides from soybeans |
| CA2522213A1 (en) | 2003-04-08 | 2004-10-28 | Dante J. Marciani | Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines |
| ES2395818T3 (es) | 2004-07-13 | 2013-02-15 | Charite - Universitatsmedizin Berlin | Composición que comprende un agente farmacológicamente activo acoplado a un componente específico de célula diana, y una saponina |
| EP1796537A4 (en) | 2004-08-25 | 2012-03-07 | Univ Michigan | DENDRIMER BASED COMPOSITIONS AND METHOD FOR THEIR USE |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 1가 항체 및 그의 제조 방법 |
| CN101563090B (zh) | 2006-11-20 | 2013-01-02 | 杜科姆公司 | 包含南美皂皮树皂苷的含脂质颗粒用于治疗癌症的用途 |
| WO2008109105A2 (en) * | 2007-03-06 | 2008-09-12 | Flagship Ventures | Methods and compositions for improved therapeutic effects with sirna |
| EP2282752A4 (en) * | 2008-03-26 | 2011-06-15 | Ca Nat Research Council | SAPONIN EXTRACT FROM SAPONARIA SPP AND ITS USES |
| WO2009126913A1 (en) | 2008-04-11 | 2009-10-15 | Cedars-Sinai Medical Center | Poly(beta malic acid) with pendant leu-leu-leu tripeptide for effective cytoplasmic drug delivery |
| WO2011054811A1 (en) | 2009-11-03 | 2011-05-12 | Santaris Pharma A/S | Rna antagonists targeting hsp27 combination therapy |
| ES2661228T3 (es) * | 2010-05-13 | 2018-03-28 | Indiana University Research And Technology Corporation | Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona |
| US9125835B2 (en) * | 2010-11-12 | 2015-09-08 | Rutgers, The State University Of New Jersey | Synergistic combinations to reduce particle dose for targeted treatment of cancer and its metastases |
| CN102652836A (zh) | 2011-03-03 | 2012-09-05 | 华中科技大学同济医学院附属协和医院 | 靶向释药的抗癌蛋白质或多肽聚合物前药及其制备方法 |
| MX2014007121A (es) | 2011-12-14 | 2014-09-04 | Seattle Genetics Inc | Nuevos conjugados de principio activo-ligante (adc) y su uso. |
| US9775915B2 (en) | 2012-11-26 | 2017-10-03 | President And Fellows Of Harvard College | Trioxacarcins, trioxacarcin-antibody conjugates, and uses thereof |
| WO2014163558A1 (en) * | 2013-04-01 | 2014-10-09 | Moreinx Ab | Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds |
| GB201400994D0 (en) * | 2014-01-21 | 2014-03-05 | Ucl Business Plc | Drug delivery system |
| ES2719584T3 (es) | 2014-04-11 | 2019-07-11 | Medimmune Llc | Compuestos conjugados que comprenden anticuerpos modificados por ingeniería genética con cisteína |
| WO2015184451A1 (en) | 2014-05-30 | 2015-12-03 | Memorial Sloan-Kettering Cancer Center | Minimal saponin analogues, synthesis and use thereof |
| TW201617368A (zh) * | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗mfi2抗體及使用方法 |
| CN106892957B (zh) * | 2015-12-17 | 2018-11-16 | 广州中医药大学 | 一种齐墩果烷型三萜皂苷类化合物及其制备方法和应用 |
| CN109641962A (zh) | 2016-06-08 | 2019-04-16 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
| AU2016423814B2 (en) | 2016-09-26 | 2023-11-23 | Desert King Chile S.A. | Production of biomass in ultra high density plantations |
| EP3652190B1 (en) | 2017-07-11 | 2023-06-14 | Freie Universität Berlin | Novel uses of a saponin and method for its isolation |
| US20220023433A1 (en) | 2018-12-21 | 2022-01-27 | Sapreme Technologies B.V. | Saponin Conjugates |
| BR112022001389A8 (pt) | 2019-07-25 | 2023-04-25 | Univ Berlin Charite | Derivados de saponina com janela terapêutica melhorada |
| WO2022055352A1 (en) | 2020-09-10 | 2022-03-17 | Sapreme Technologies B.V. | Semicarbazone-based saponin conjugate |
| CA3240612A1 (en) * | 2021-12-22 | 2023-06-29 | Miriam Verena Bujny | Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders |
-
2019
- 2019-12-09 US US17/312,104 patent/US20220023433A1/en active Pending
- 2019-12-09 EP EP23170913.0A patent/EP4241847B1/en active Active
- 2019-12-09 CN CN202510019306.XA patent/CN119950740A/zh active Pending
- 2019-12-09 WO PCT/EP2019/000334 patent/WO2020126064A1/en not_active Ceased
- 2019-12-09 JP JP2021536407A patent/JP7652695B2/ja active Active
- 2019-12-09 US US17/312,403 patent/US20220111066A1/en not_active Abandoned
- 2019-12-09 SG SG11202106664PA patent/SG11202106664PA/en unknown
- 2019-12-09 AU AU2019400630A patent/AU2019400630B2/en active Active
- 2019-12-09 WO PCT/EP2019/084210 patent/WO2020126609A2/en not_active Ceased
- 2019-12-09 AU AU2019411276A patent/AU2019411276A1/en active Pending
- 2019-12-09 EP EP19817673.7A patent/EP3897738B1/en active Active
- 2019-12-09 WO PCT/EP2019/084290 patent/WO2020126626A1/en not_active Ceased
- 2019-12-09 CN CN201980092811.XA patent/CN113474010A/zh active Pending
- 2019-12-09 BR BR112021012222A patent/BR112021012222A8/pt not_active Application Discontinuation
- 2019-12-09 KR KR1020217023032A patent/KR102894465B1/ko active Active
- 2019-12-09 ES ES21186481T patent/ES3072667T3/es active Active
- 2019-12-09 KR KR1020217022975A patent/KR20210110323A/ko active Pending
- 2019-12-09 SG SG11202106606RA patent/SG11202106606RA/en unknown
- 2019-12-09 MX MX2021007449A patent/MX2021007449A/es unknown
- 2019-12-09 WO PCT/EP2019/084190 patent/WO2020126604A1/en not_active Ceased
- 2019-12-09 CN CN202510084422.XA patent/CN119868574A/zh active Pending
- 2019-12-09 EP EP19817689.3A patent/EP3897735B1/en active Active
- 2019-12-09 CA CA3124065A patent/CA3124065A1/en active Pending
- 2019-12-09 WO PCT/EP2019/084292 patent/WO2020126627A1/en not_active Ceased
- 2019-12-09 DK DK19817673.7T patent/DK3897738T5/da active
- 2019-12-09 JP JP2021536411A patent/JP7541008B2/ja active Active
- 2019-12-09 AU AU2019411278A patent/AU2019411278B2/en active Active
- 2019-12-09 CA CA3124151A patent/CA3124151A1/en active Pending
- 2019-12-09 WO PCT/EP2019/084211 patent/WO2020126610A1/en not_active Ceased
- 2019-12-09 EP EP20209450.4A patent/EP3808379A1/en active Pending
- 2019-12-09 EP EP21186481.4A patent/EP3915587B1/en active Active
- 2019-12-09 DK DK19817689.3T patent/DK3897735T3/da active
- 2019-12-09 JP JP2021536414A patent/JP7593925B2/ja active Active
- 2019-12-09 ES ES19835231T patent/ES2899612T3/es active Active
- 2019-12-09 KR KR1020217023069A patent/KR20210119979A/ko not_active Ceased
- 2019-12-09 ES ES23170913T patent/ES3038616T3/es active Active
- 2019-12-09 SG SG11202106672SA patent/SG11202106672SA/en unknown
- 2019-12-09 PT PT198176893T patent/PT3897735T/pt unknown
- 2019-12-09 EP EP25172979.4A patent/EP4588523A3/en active Pending
- 2019-12-09 AU AU2019411289A patent/AU2019411289B2/en active Active
- 2019-12-09 US US17/413,965 patent/US20250195682A1/en not_active Abandoned
- 2019-12-09 AU AU2019407234A patent/AU2019407234B2/en active Active
- 2019-12-09 SG SG11202106575YA patent/SG11202106575YA/en unknown
- 2019-12-09 AU AU2019408811A patent/AU2019408811B2/en active Active
- 2019-12-09 KR KR1020257035339A patent/KR20250160210A/ko active Pending
- 2019-12-09 US US17/312,311 patent/US20230173085A1/en not_active Abandoned
- 2019-12-09 KR KR1020217023071A patent/KR20210117274A/ko not_active Ceased
- 2019-12-09 ES ES19817689T patent/ES3059876T3/es active Active
- 2019-12-09 KR KR1020217023075A patent/KR20210107073A/ko not_active Ceased
- 2019-12-09 CN CN201980092709.XA patent/CN113507941A/zh active Pending
- 2019-12-09 EP EP19817677.8A patent/EP3897739B1/en active Active
- 2019-12-09 US US17/312,019 patent/US12453782B2/en active Active
- 2019-12-09 CA CA3124129A patent/CA3124129A1/en active Pending
- 2019-12-09 ES ES19817677T patent/ES2985240T3/es active Active
- 2019-12-09 CA CA3304910A patent/CA3304910A1/en active Pending
- 2019-12-09 CN CN201980092610.XA patent/CN113498350A/zh active Pending
- 2019-12-09 WO PCT/EP2019/084242 patent/WO2020126620A2/en not_active Ceased
- 2019-12-09 KR KR1020217023076A patent/KR20210117276A/ko active Pending
- 2019-12-09 SG SG11202106574UA patent/SG11202106574UA/en unknown
- 2019-12-09 DK DK19835231.2T patent/DK3773737T3/da active
- 2019-12-09 EP EP19835231.2A patent/EP3773737B1/en active Active
- 2019-12-09 EP EP19817672.9A patent/EP3897743A1/en active Pending
- 2019-12-09 CA CA3124406A patent/CA3124406A1/en active Pending
- 2019-12-09 EP EP23166479.8A patent/EP4223316A3/en active Pending
- 2019-12-09 CN CN201980092673.5A patent/CN113747923A/zh active Pending
- 2019-12-09 EP EP19820708.6A patent/EP3897741A1/en active Pending
- 2019-12-09 CA CA3123978A patent/CA3123978A1/en active Pending
- 2019-12-09 SG SG11202106612QA patent/SG11202106612QA/en unknown
- 2019-12-09 ES ES21212184T patent/ES2952017T3/es active Active
- 2019-12-09 US US17/312,193 patent/US20220054643A1/en active Pending
- 2019-12-09 JP JP2021536413A patent/JP7654546B2/ja active Active
- 2019-12-09 CN CN201980092858.6A patent/CN113474009A/zh active Pending
- 2019-12-09 EP EP25203109.1A patent/EP4647436A3/en active Pending
- 2019-12-09 PT PT212121842T patent/PT4015003T/pt unknown
- 2019-12-09 EP EP19817676.0A patent/EP3897742A2/en active Pending
- 2019-12-09 IL IL284280A patent/IL284280B1/en unknown
- 2019-12-09 DK DK21212184.2T patent/DK4015003T5/da active
- 2019-12-09 CA CA3124064A patent/CA3124064A1/en active Pending
- 2019-12-09 JP JP2021536412A patent/JP7614094B2/ja active Active
- 2019-12-09 US US17/312,476 patent/US20220072149A1/en active Pending
- 2019-12-09 EP EP19817682.8A patent/EP3856254A2/en active Pending
- 2019-12-09 WO PCT/EP2019/084180 patent/WO2020126600A1/en not_active Ceased
- 2019-12-09 EP EP21212184.2A patent/EP4015003B1/en active Active
- 2019-12-09 JP JP2021536410A patent/JP7502301B2/ja active Active
- 2019-12-09 US US17/415,759 patent/US20220218837A1/en active Pending
- 2019-12-09 MX MX2021007296A patent/MX2021007296A/es unknown
- 2019-12-09 SG SG11202106572QA patent/SG11202106572QA/en unknown
- 2019-12-09 KR KR1020217023074A patent/KR20210117275A/ko active Pending
- 2019-12-09 CN CN201980092771.9A patent/CN113453722A/zh active Pending
- 2019-12-09 SG SG11202106603UA patent/SG11202106603UA/en unknown
- 2019-12-09 BR BR112021012225A patent/BR112021012225A8/pt not_active IP Right Cessation
- 2019-12-09 KR KR1020217023063A patent/KR20210119978A/ko not_active Ceased
- 2019-12-09 EP EP24169240.9A patent/EP4374927A3/en active Pending
-
2021
- 2021-06-21 IL IL284279A patent/IL284279A/en unknown
- 2021-06-21 IL IL284272A patent/IL284272A/en unknown
- 2021-06-21 IL IL284274A patent/IL284274A/en unknown
- 2021-06-21 IL IL284278A patent/IL284278A/en unknown
- 2021-06-21 IL IL284265A patent/IL284265A/en unknown
- 2021-06-21 IL IL284273A patent/IL284273A/en unknown
- 2021-06-21 IL IL284276A patent/IL284276A/en unknown
-
2024
- 2024-11-15 JP JP2024199932A patent/JP2025015702A/ja active Pending
- 2024-12-16 US US18/981,715 patent/US20250302983A1/en active Pending
- 2024-12-26 JP JP2024230339A patent/JP2025041928A/ja active Pending
-
2025
- 2025-02-04 US US19/044,661 patent/US20260000783A1/en active Pending
- 2025-03-13 JP JP2025040440A patent/JP2025090776A/ja active Pending
- 2025-03-19 JP JP2025046059A patent/JP2025102831A/ja active Pending
- 2025-03-19 JP JP2025046058A patent/JP2025094140A/ja active Pending
- 2025-03-28 AU AU2025202242A patent/AU2025202242B2/en active Active
- 2025-04-29 AU AU2025203017A patent/AU2025203017A1/en active Pending
- 2025-04-30 AU AU2025203092A patent/AU2025203092A1/en active Pending
-
2026
- 2026-07-14 AU AU2026206076A patent/AU2026206076A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284276A (en) | Saponin conjugates | |
| IL286291A (en) | Compounds and conjugates thereof | |
| DK3579883T3 (da) | Pyrrolobenzodiazepin-antistofkonjugater | |
| EP3807644A4 (en) | ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | |
| DK3592393T3 (da) | Frigørbare konjugater | |
| DK3794042T5 (da) | Anti-muc1-exatecet-antistof-lægemiddelkonjugat | |
| EP3554266A4 (en) | ANTIBODY-DRUG CONJUGATES MULTI-DRUG | |
| EP3555124C0 (en) | TCR NYESO | |
| LT3525830T (lt) | Pirolbenzodiazepino konjugatai | |
| EP3793613C0 (en) | IMMUNOCONJUGATES | |
| LT3544636T (lt) | Pirolobenzodiazepino-antikūno konjugatai | |
| EP3643932A4 (en) | LINKAGE MECHANISM | |
| EP3781060A4 (en) | CRYOPROBE | |
| DK3612537T3 (da) | Pyrrolobenzodiazepinkonjugater | |
| DK3737403T5 (da) | Modificerede adenovira | |
| IL281051A (en) | Immunoconjugates targeting egfr | |
| EP3784463A4 (en) | Fluorosulfones | |
| DK3544634T3 (da) | MET-antistof-lægemiddelkonjugater | |
| HUE061610T2 (hu) | Készítmény | |
| IL283279A (en) | Bi-specific conjugates | |
| DK3672442T3 (da) | Foldemekanisme | |
| FI11939U1 (fi) | Teline | |
| EP3768623A4 (en) | ALIGNMENT ARRANGEMENT | |
| EP3721129C0 (en) | Cryosphere | |
| EP3986939A4 (en) | TWO-DRUG ANTIBODY-DRUG CONJUGATE |